Why Whole Foods is Hot
Health Care: Drugs
Idenix Pharmaceuticals Inc. (IDIX: NASDAQ)
$4.15 0.08 | 1.97%
05/22/13 - 04:00 PM ET
Latest Dividend:0.00
Latest Dividend Yield:0.00%
Dividend Ex-Date:12/31/69
Price Earnings Ratio:n/a
Price Earnings Comparisons:
| IDIX | Sector Avg. | S&P 500 |
|---|---|---|
| n/a | 0.00 | 17.70 |
Price Performance History (% change):
| 3 Mo | 1 Yr | 3 Yr |
|---|---|---|
| -11.52 | -50.12 | 16.62 |
| GROWTH | 12 Mo | 3 Yr | CAGR |
|---|---|---|---|
| Revenue | 902.20 | 4.52 | 0.76 |
| Net Income | -0.39 | 0.00 | |
| EPS | -0.69 | 0.00 |
Earnings for IDIX:
| EBITDA | -27.00 |
| REVENUE | 69.66M |
Average Earnings Estimates
| Qtr (06/13) | Qtr (09/13) | FY (12/13) | FY (12/14) | |
|---|---|---|---|---|
| Average Estimate | $-0.22 | $-0.23 | $-0.87 | $-0.78 |
| Number of Analysts | 8 | 8 | 11 | 12 |
| High Estimate | $-0.18 | $-0.18 | $-0.72 | $-0.20 |
| Low Estimate | $-0.26 | $-0.32 | $-1.07 | $-1.23 |
| Prior Year | $-0.23 | $0.03 | $-0.23 | $-0.87 |
| Growth Rate (Year over Year) | 3.26% | -870.83% | -277.87% | 10.83% |
Portfolios with IDIX
- Portfolio NameUser Type
- ProSeth Klarman - Baupost Group
- ContributorBreakout Stocks Of The Week...
- ContributorBreakout Stocks Of The Week...
- ContributorMost-Active Stocks for the ...
- ContributorStocks Under-$10 Moving Hig...
- Userdonnieny7 Portfolio 1 Specu...
- ContributorStocks Rising On Unusual Vo...
- Usernew
- UserLong Term Stock Picks
- ContributorStocks Under-$10 Setting Up...
Latest IDIX Headlines from TheStreet
- Idenix Announces Data Presentation At The 48th Annual Meeting Of The European Association For The Study Of The Liver (EASL) 04.08.13 | 04:04 pm
- Idenix Loses First Phase Of Patent Dispute With Gilead Sciences 03.25.13 | 07:03 am
- Stock Futures Rise as Cyprus Deal Is Clinched 03.25.13 | 06:03 am
- Idenix Pharmaceuticals Announces Decision By The United States Patent And Trademark Office Patent Trial And Appeal Board In The First Phase Of The Interference 03.22.13 | 04:03 pm
- Idenix Pharmaceuticals To Present At Two Upcoming Investor Conferences 02.26.13 | 04:02 pm
- Idenix Pharmaceuticals Reports Fourth Quarter And Year Ended 2012 Financial Results 02.25.13 | 04:02 pm
- Fisking Ray Dirks on Medgenics and Shaming Seeking Alpha 02.11.13 | 09:02 pm
- Biotech Stock Mailbag: Dynavax, ImmunoCellular, Celldex and Medgenics 02.08.13 | 06:02 am
- Idenix Pharmaceuticals To Present At Two Upcoming Investor Conferences 02.05.13 | 04:02 pm
- Idenix Pharmaceuticals Provides Update On IDX184 And IDX19368 Development Programs 02.04.13 | 04:02 pm
Press Releases for IDIX
- Idenix Pharmaceuticals Announces Declaration Of A Patent Interference By The USPTO - PR Newswire 03.06.12 | 08:03 am
- Idenix Pharmaceuticals Elects Thomas Hodgson As Chairman Of The Board And Appoints Michael Wyzga To Its Board Of Directors - PR Newswire 03.01.12 | 04:03 pm
- Idenix Pharmaceuticals To Present At Three Upcoming Investor Conferences - PR Newswire 02.29.12 | 04:02 pm
- Idenix Pharmaceuticals To Present At The Citi Global Healthcare Conference - PR Newswire 02.21.12 | 04:02 pm
- Idenix To Host Conference Call Discussing Fourth Quarter And Year End 2011 Financial Results And Pipeline Update - PR Newswire 02.16.12 | 08:02 am
- Idenix Pharmaceuticals To Present At Two Upcoming Investor Conferences - PR Newswire 02.07.12 | 04:02 pm
- BioMed Realty Trust To Acquire Cambridge Place For $119 Million - PR Newswire 02.06.12 | 05:02 pm
- Idenix Announces Removal Of The Partial Clinical Hold On HCV Nucleotide Inhibitor, IDX184 - PR Newswire 02.03.12 | 08:02 am
- Idenix Reports Advancement Of HCV Development Pipeline - PR Newswire 01.09.12 | 07:01 am
- Idenix Reports Positive Interim Data For HCV Nucleotide Inhibitor, IDX184 - PR Newswire 01.09.12 | 07:01 am
Partner Headlines for IDIX
- DFC Global Lowers Outlook and 2 Other Stocks At 52-Week Lows - Wall St. Cheat Sheet 04.02.13 | 09:04 am
- Biotech Weekly Recap: Loads Of Bullishness, 2 Giant Rallies, And Selling - Seeking Alpha 12.02.12 | 09:12 am
- RIM, Green Mountain and Other Top Performing Nasdaq Stocks in November - Benzinga 12.01.12 | 01:12 pm
- New Second Generation Combination Therapy For HCV - First Or Best In The Market - Part 3 - Seeking Alpha 11.30.12 | 08:11 am
- UPDATE: Deutsche Bank Initiates Coverage on Idenix Pharmaceuticals with Buy Rating, $7 PT - Benzinga 11.28.12 | 09:11 am
- Morning Market Losers - Benzinga 09.19.12 | 09:09 am
- Idenix's Candidate on Clinical Hold - Analyst Blog - NASDAQ 08.30.12 | 10:08 pm
- Bad News for Bristol-Myers - Analyst Blog - NASDAQ 08.27.12 | 10:08 pm
- Bad News for Bristol-Myers - Analyst Blog - Zacks 08.27.12 | 06:08 pm
- UPDATE: Oppenheimer Maintains Idenix Pharmaceuticals at Perform Following Clinical Hold on IDX19368 - Benzinga 08.27.12 | 01:08 pm
